Last reviewed · How we verify
Palonosetron only
Palonosetron is a highly selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting.
Palonosetron is a highly selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting. Used for Prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy, Prevention of post-operative nausea and vomiting (PONV), Prevention of nausea and vomiting associated with moderately emetogenic chemotherapy.
At a glance
| Generic name | Palonosetron only |
|---|---|
| Also known as | Palonosetron, Saline Solution |
| Sponsor | NYU Langone Health |
| Drug class | 5-HT3 receptor antagonist |
| Target | 5-HT3 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology / Supportive Care |
| Phase | FDA-approved |
Mechanism of action
Palonosetron binds with high affinity and selectivity to 5-hydroxytryptamine type 3 (5-HT3) receptors, which are located on vagal afferents in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By antagonizing these receptors, it prevents the emetic signal cascade triggered by chemotherapy, radiation, or post-operative conditions. It has a longer half-life and greater receptor binding affinity compared to earlier-generation 5-HT3 antagonists.
Approved indications
- Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
- Prevention of post-operative nausea and vomiting (PONV)
Common side effects
- Headache
- Constipation
- Diarrhea
- Dizziness
Key clinical trials
- AKY15-HK-301_NEPA Study (PHASE2)
- Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC) (PHASE2)
- A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteers (PHASE1)
- Protreat-Trial: Prophylactic Antiemetic Treatment of Opioid-induced Nausea and Vomiting (OINV) in Palliative Care (PHASE2)
- Effect of SAR302503 on ECG Activity in Patients With Solid Tumors (PHASE1)
- Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer (PHASE4)
- Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP (NA)
- PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Palonosetron only CI brief — competitive landscape report
- Palonosetron only updates RSS · CI watch RSS
- NYU Langone Health portfolio CI